/
Metabolic & Endocrine
Hypoglycemia
20
Pipeline Programs↗
10
Active Trials↗
14
Companies Involved↗
Hypoglycemia is an emerging landscape with 20 programs across 14 companies. The most active players are Amylyx Pharmaceuticals Inc., RECORDATI GROUP. 1 program is in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical16
Phase 1
No programs
Phase 23
Approved
No programs
Analysis
Modality Breakdown
84%
Small molecule
16 of 19 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 19 classified programs, each share of the total. Modality classified for 100% of 20 pipeline programs.
Analysis
Trial Status
101
clinical trials
Completed57 · 56%
Terminated13 · 13%
Unknown status9 · 9%
Withdrawn7 · 7%
Active, not recruiting5 · 5%
Recruiting4 · 4%
Other6 · 6%
Clinical Trials
Trial Activity
101 trials
Fasting Hypoglycemia: Diagnosis and Treatment
Recruiting·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·N/A·NCT00001276·1,500 enrolled
Restoration of Hypoglycemia Awareness With Metoclopramide
Recruiting·—·Phase 2·NCT03970720·36 enrolled
Liver Glycogen and Hypoglycemia in Humans
Active, not recruiting·—·Phase 1·NCT03241706·40 enrolled
Page 1 of 7
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)